Sagimet Biosciences(SGMT.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Sagimet Biosciences
SGMT.US
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc.
1.951 T
SGMT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely

    Sagimet Biosciences (NASDAQ:SGMT) has a cash runway of approximately 2.6 years, with $117 million in cash and a cash burn of $45 million per year. Although the company's cash burn increased by 16% over the last year, indicating a focus on growth, this raises concerns about potential dilution if new shares are issued to cover future expenses. Despite the risks associated with cash-burning companies, the current cash runway is considered promising, though investors should be aware of three warning signs identified in the company's analysis.

    Simplywall·
    US
    SGMT
    -1.79%
    Simplywall·
    US
    SGMT
    -1.79%

    Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target

    Debanjana Chatterjee from JonesTrading has maintained a Buy rating on Sagimet Biosciences, Inc. Class A, with a price target of $26. The rating is supported by the company's advancing pipeline, strong clinical momentum, and strategic positioning. Key factors include favorable Phase 1 data for deni-resmetirom, upcoming regulatory interactions, and the potential of FASN inhibitors in various indications. Chatterjee also highlights the competitive acne data and the long-term development pathway strengthened by the TAPI licensing agreement, reinforcing confidence in the company's execution and growth prospects.

    Tip Ranks·
    US
    SGMT
    -1.79%
    Tip Ranks·
    US
    SGMT
    -1.79%

    After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally

    Several biotech companies saw significant gains in after-hours trading, driven by corporate updates and acquisition speculation. China SXT Pharmaceuticals (SXTC) rose 13.6% after launching an AI initiative. Revolution Medicines (RVMD) surged 15.1% following reports of Merck's acquisition talks and FDA breakthrough designation for its drug. KalVista Pharmaceuticals (KALV) advanced 14% on positive revenue results. Other notable gainers included Zentalis Pharmaceuticals (ZNTL), BriaCell Therapeutics (BCTX), Equillium (EQ), and Sagimet Biosciences (SGMT), each experiencing increases without major new announcements.

    rttnews·
    US
    KALV
    -6.93%
    US
    SGMT
    -1.79%
    US
    SXTC
    -3.97%
    rttnews·
    US
    KALV
    -6.93%
    US
    SGMT
    -1.79%
    US
    SXTC
    -3.97%

    Sagimet Highlights Positive MASH Combo Data and Pipeline Progress

    Sagimet Biosciences reported positive results from a Phase 1 trial of its FASN inhibitor denifanstat combined with resmetirom for MASH. The company plans a Phase 2 trial in 2026. Additionally, a Phase 3 acne trial in China met all endpoints, and a new drug application was accepted. Sagimet's financials show substantial difficulties, with a recent analyst rating of 'Buy' and a $26.00 price target. The company has $125.5 million in cash and expects to fund operations for two years.

    Tip Ranks·
    US
    SGMT
    -1.79%
    Tip Ranks·
    US
    SGMT
    -1.79%

    Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH

    Sagimet Biosciences Inc. announced positive Phase 1 results for the combination of denifanstat and resmetirom in a clinical trial. The study, involving 40 healthy adults, showed the combination was well-tolerated with no serious adverse events. Sagimet plans to advance to a Phase 2 trial for MASH patients with F4 fibrosis in the second half of 2026.

    Reuters·
    US
    SGMT
    -1.79%
    Reuters·
    US
    SGMT
    -1.79%
    © 2026 Longbridge｜Disclaimer